ADE (chemotherapy) explained
ADE is a chemotherapy regimen most often used as an induction or consolidation regimen in acute myelogenous leukemia, especially in poor-risk patients or those refractory to the standard first-line induction with standard "7+3" regimen or who are relapsed after the standard chemotherapy.
ADE regimen consists of three drugs:
- Ara-C (cytarabine) - an antimetabolite;
- Daunorubicin - an anthracycline antibiotic that is able to intercalate DNA and thus disrupt the cell division cycle, preventing mitosis;
- Etoposide - a topoisomerase inhibitor.[1]
Dosing regimen
| Drug | Dose | Mode | Days |
|---|
| 200 mg/m2 | IV push every 12 hours in 2 divided doses (100 mg/m2 each) | Days 1-10 |
| 50 mg/m2 | IV slow push | Days 1, 3 and 5 |
| 100 mg/m2 | IV infusion over 1 hour | Days 1-5 |
|
Notes and References
- Web site: Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial . 2014-09-15 . 2015-09-23 . https://web.archive.org/web/20150923193753/http://www.bloodjournal.org/content/107/12/4614.abstract?sso-checked=true . live .
